ABBV-184

N/A

Report date: 2026/03/19 17:22:22

Base Information

Drug NameABBV-184

Drug Alias NameABBV-184

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionBaculoviral IAP repeat-containing protein 5 inhibitorsAnti-CD3

TargetsBaculoviral IAP repeat-containing protein 5T cell surface glycoprotein CD3

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, AcuteNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited KingdomFrance +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, AcuteNeoplasms

Other Information

ATC CodeN/A